Pharbinex-PE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Pharbinex-PE
- Generic name
- GUAIFENESIN 400MG AND PHENYLEPHRINE HCL 10MG
- Manufacturer
- Ulai Health LLC
- Product type
- HUMAN OTC DRUG
- SPL set ID
- e459bb83-b1d6-42fc-aa46-99ad117e6144
- SPL ID
- 2c2a2804-8a2b-be5d-e063-6394a90a9763
- Version
- 3
- Effective date
- 2025-01-20
- Source export date
- 2026-09-28
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/ae3816359e336a5de4f44607730a3d12ceb61ffa012a132189ceda22541b38ee/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:53:56
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application number | M012 | openfda.application_number | |
| brand name | Pharbinex-PE | openfda.brand_name | |
| generic name | GUAIFENESIN 400MG AND PHENYLEPHRINE HCL 10MG | openfda.generic_name | |
| manufacturer name | Ulai Health LLC | openfda.manufacturer_name | |
| ndc | package | 73057-389-04 | openfda.package_ndc |
| ndc | product | 73057-389 | openfda.product_ndc |
| ndc11 | package | 73057038904 | derived:openfda.package_ndc |
| rxcui | 1304111 | openfda.rxcui | |
| spl id | 2c2a2804-8a2b-be5d-e063-6394a90a9763 | id | |
| spl set id | e459bb83-b1d6-42fc-aa46-99ad117e6144 | set_id | |
| unii | 04JA59TNSJ | openfda.unii | |
| unii | 495W7451VQ | openfda.unii |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.